Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
eNq1mE1z2jAQhu/8Co8PveEPEgJpbTItTVpmkiklYdrphRH2EkSF5OiDkP76ypg0pCM3qUBHW/a7K+3q0TtKztZL4q2AC8xo6sdB5HtAM5Zjepv645uLZtc/6zWSBVqhnc86QRTELd/LCBIi9cvRYAqIiuD71eVH0P8D93sNL2HTBWTy2XdKYhJ8RmJ+hYryGy9ZMZx7S5Bzlqd+oeTmrZcIyXUWvXvGf4oCZZCE2ze7o4vJ8e77JCzFXqGqBPBLRG+NokCtNDPFOVDZRxJuGX+oyffIShuLEQimeAZDJOdDzlY4h9wYYoaIAKsgs/v8GviKgCyDGMXDRbYUVuJogdYjuBuYk36vR/tyLZtRM+502vFx97QVRScnVqH4zlKZq6AnEWaTuNOK4lYnBBoSlenSYWFZnCHjEhFHZcGi/7yzHMXhcPdi+XMsCoIegoUobJcKcaSHgev9724i5QxuuCYS0Wv2lz5VhIT/mfV4ywtHGZc46jNFZQ02Lka2C9FnVMK6vqJ2pJPrbS9iEIeT/cWomfJDNSU4s2Wapo4CIcejQT3SDkqDD0jAmLvDwTdMc3YvDo+Z3bI6yr7YkNIoWvA8nrROuydxu229i37oHqo5Y84VZwWEGkCWld1yZUBnbF+i6LY0Sz025eH6cWN1WIYI1JidpiVddCM+ejNnre5uG1UDRtFP5ze2/fFVAX+43jwapXGe/qmsHXpd8Fx340uJV/s2LSZHUbt7enT8Bi2Ld48uOrV0zJWoE8OsuBkycykL8TYM50g0BdJrGcz4P06AM+O8DzF3jdunUroz9E7O/8oPVah1lPq0OkNfX0PbHfuSO9jX8W7/3zprYwzJFexRhwruzhA8OD881Z/srrO0h8/Y4i7MxpoiiRl15ZjU1Ki43zmi60ovuIbDl9kM11yu1PZlElYXO71GEpaXOr3GbzaW/t0=
GU77UK6HeE8g9Ws4
